Conversion therapy with chemoimmunotherapy induced pCR in a stage IV lung squamous cell carcinoma patient harboring EGFR exon 20 insertion
Authors:
Open Access
- 28 November 2024
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2431384
Abstract
This case study details an innovative conversion therapy strategy in a 58-year-old Asian male with baseline stage cT4N1M1b advanced lung squamous cell carcinoma (SCC) harboring a rare EGFR exon 20 insertion mutation with concurrent high PD-L1 expression who achieved a pathologic complete response (pCR) after preoperative immunotherapy plus chemotherapy. The patient initially presented with coughing and bloody sputum and was comprehensively diagnosed via PET/CT scanning, bronchoscopic biopsy and next-generation sequencing. After four cycles of platinum‒paclitaxel chemotherapy plus immunotherapy with pembrolizumab (a PD-1 blockade), significant primary tumor shrinkage and the disappearance of oligometastasis in the right adrenal gland were discovered via CT scans. The subsequent salvage lung surgery resulted in a pCR, and the patient continued postoperative maintenance immunotherapy. No evidence of disease relapse or immune-related adverse events occurred after a post-surgery follow-up time of 9.4 months. This case highlights the potential value and challenges of immunotherapy plus chemotherapy as conversion therapy strategy in treating patients with non-small cell lung cancer (NSCLC) harboring rare EGFR exon 20 insertions.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2023MH259)
This publication has 30 references indexed in Scilit:
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2021
- TargetingEGFRExon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical UpdatesCancer Discovery, 2021
- Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature reviewPLOS ONE, 2021
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II TrialCancer Discovery, 2021
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialNature Medicine, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: A phase II studyThe Journal of Thoracic and Cardiovascular Surgery, 2021
- EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsCancer Treatment Reviews, 2020
- Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II StudyJournal of Clinical Oncology, 2019
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancerOncoImmunology, 2017